Form D · Biotechnology
Glycomine, Inc.
San Francisco, CA · CIK 0001689792
Offering snapshot reported Nov 10, 2016 · SEC filing
- Reported sold
- $4.93M Offering amount: $12.6M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 27, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2016 | Initial | $4,934,331 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-274291
Remainder to be sold is subject to satisfaction of certain milestones.
Source: Form D, filed Nov 10, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Giacomo Chiesi | Director |
| Peter C.M. Mc Williams | Director |
| Agnes Rafalko | Director, Executive |
| Christopher Starr | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
953 Indiana Street
San Francisco, CA, 94107
San Francisco, CA, 94107